Dr. Hanham has served as a member of the board of directors since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm, from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. (Nasdaq: ITMN). From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceutical, Inc. and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals Inc. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson and Company (Nasdaq: BDX) in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Dr. Hanham currently serves on the board of HTC Molecular Diagnostics Inc. (Nasdaq: HTGM). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.
Links